What Is Retatrutide?
Retatrutide (LY3437943) is an investigational medication developed by Eli Lilly. Unlike semaglutide, which activates only the GLP-1 receptor, and tirzepatide, which activates GLP-1 and GIP, retatrutide is a triple-receptor agonist — it simultaneously activates GLP-1, GIP, and glucagon receptors.
This matters because it targets three dimensions of metabolism at once: appetite suppression (GLP-1), insulin sensitivity and energy storage (GIP), and energy expenditure through fat oxidation (glucagon). No existing FDA-approved weight-loss medication engages all three pathways simultaneously.
Retatrutide at a Glance
Where Can I Get Retatrutide Near Me?
If you are searching for “retatrutide near me” in the Dallas-Fort Worth area, LuxeFit Wellness offers physician-prescribed retatrutide protocols through licensed compounding pharmacy partners. The process is designed to be medically rigorous — not a click-to-buy transaction.
Complete Health Intake
Fill out a comprehensive online health questionnaire on our TelehealthCash partner platform.
Virtual Physician Consultation
Meet with a licensed physician via secure video to discuss your goals, health history, and whether retatrutide is clinically appropriate.
Physician Review
The physician evaluates your candidacy, screens for contraindications, and determines the appropriate protocol.
Pharmacy Dispensing & Shipping
If approved, your prescription is sent to a licensed compounding pharmacy and shipped to your door.
Areas served: Dallas, Fort Worth, Plano, Frisco, Irving, Arlington, Garland, McKinney, Grapevine, Southlake, and the broader DFW metroplex. Virtual consultations are available to patients nationwide where legally permitted and clinically appropriate.
Retatrutide vs Semaglutide vs Tirzepatide
| Semaglutide | Tirzepatide | Retatrutide | |
|---|---|---|---|
| Mechanism | GLP-1 only | GIP + GLP-1 | GIP + GLP-1 + Glucagon |
| FDA Status | Approved | Approved | Investigational |
| Avg Weight Loss | ~15% | ~22% | ~24% (Phase 2) |
| Developer | Novo Nordisk | Eli Lilly | Eli Lilly |
| Brand Name | Wegovy / Ozempic | Zepbound / Mounjaro | None (investigational) |
| Dosing | Once-weekly injection | Once-weekly injection | Once-weekly injection |
Weight-loss figures are cross-trial comparisons from separate pivotal studies; they are not head-to-head data. Head-to-head Phase 3 data for retatrutide vs tirzepatide (TRIUMPH-5, NCT06662383) is expected by late 2026.
Clinical Trial Data
The Phase 2 trial, published in the New England Journal of Medicine, enrolled 338 adults with obesity and evaluated retatrutide at doses from 1mg to 12mg over 48 weeks.
Key Phase 2 Findings
- ✦Average weight loss of 24.2% at 48 weeks on the 12mg dose — the highest ever reported in a non-surgical obesity intervention.
- ✦Participants were still losing weight at week 48 with no plateau, suggesting longer treatment could produce greater reductions.
- ✦Significant reductions in hepatic fat fraction in participants with NAFLD, driven by the triple mechanism.
- ✦Substantial improvements in insulin sensitivity, blood pressure, and lipid profiles.
- ✦Heart rate increases of 4-6 bpm, consistent with glucagon receptor activation — managed through slow titration.
- ✦GI side effects consistent with GLP-1 class: nausea, vomiting, diarrhea, most common during dose escalation.
Eli Lilly's Phase 3 TRIUMPH program is currently underway, including TRIUMPH-5 (NCT06662383), a head-to-head trial comparing retatrutide to tirzepatide in 800 adults with obesity. Primary completion is estimated for December 2026.
All clinical data referenced comes from published trial results available on ClinicalTrials.gov and PubMed. Retatrutide is investigational — efficacy and safety have not been reviewed or confirmed by the FDA for any indication.
Important Considerations Before Seeking Retatrutide
- Retatrutide is not FDA-approved as of July 2026. It is an investigational medication.
- Compounded retatrutide is not the same as an FDA-approved branded product — it is prepared by a compounding pharmacy under physician prescription.
- Eligibility requires a thorough medical evaluation. Not everyone is a candidate.
- Common side effects include nausea, vomiting, diarrhea, and heart rate elevation.
- Patients with a personal or family history of medullary thyroid carcinoma or MEN2 should not take GLP-1 class medications.
- There is no insurance coverage for retatrutide — all costs are cash-pay.
Frequently Asked Questions
What is retatrutide?
Retatrutide is Eli Lilly's investigational triple-receptor agonist that targets GLP-1, GIP, and glucagon receptors simultaneously. Phase 2 data published in the New England Journal of Medicine showed average weight loss of 24.2% at 48 weeks on the 12mg dose. It is not FDA-approved as of July 2026.
Where can I get retatrutide near me?
If you are in the Dallas-Fort Worth metroplex (Dallas, Plano, Frisco, Fort Worth, or nearby), LuxeFit Wellness offers physician-prescribed retatrutide access through licensed compounding pharmacy partners. The process begins with a virtual consultation where a licensed physician reviews your health history. LuxeFit Wellness serves patients nationwide through its telehealth platform.
Is retatrutide FDA-approved?
No. As of July 2026, retatrutide is not FDA-approved for any indication. It remains in Phase 3 clinical trials. Compounded retatrutide, when prescribed by a physician, is a legal and regulated preparation — but it is not the same as an FDA-approved branded product.
How much does retatrutide cost?
Retatrutide at LuxeFit Wellness starts at $699/vial under cash-pay, physician-prescribed protocols. There is no insurance coverage or manufacturer coupon, as the drug is not yet FDA-approved. All costs are discussed transparently during the consultation.
What are the side effects of retatrutide?
The most common side effects are gastrointestinal: nausea, vomiting, diarrhea, and constipation. A heart rate increase of 4-6 bpm has been observed. As with all GLP-1 therapies, screening for thyroid cancer risk, pancreatitis history, and gallbladder disease is essential.
Do I need a prescription for retatrutide?
Yes. Retatrutide is a prescription-only therapy that requires evaluation by a licensed physician. It is not available over the counter or without a valid prescription.
Ready to Explore Retatrutide?
Schedule a virtual consultation with a licensed physician to determine whether retatrutide or another GLP-1 peptide therapy is right for your goals.
Start Your ConsultationThis page is for educational purposes only and does not constitute medical advice. Retatrutide is an investigational medication that is not FDA-approved. Information on this website should not be used to diagnose, treat, or prevent any medical condition. Compounded medications are not FDA-approved. Consult with a licensed physician before starting any new therapy. LuxeFit Wellness is a patient management platform that partners with independent licensed physician networks. LuxeFit Wellness does not directly provide medical or pharmacy services. Medical services are rendered by independent providers.